Skip to main content

Conmed Value Stock - Dividend - Research Selection

Conmed

ISIN: US2074101013 , WKN: 886793

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. It offers orthopedic surgery products under Hall, CONMED Linvatec, Concept, and Shutt brands. The company also offers general surgery product in the areas of advanced surgical comprising clinical insufflation system; electrosurgical products; endomechanical products comprising instruments, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors; and uterine manipulator (VCARE) for use in increasing the efficiency of laparoscopic hysterectomies and other gynecologic laparoscopic procedures. In addition, it offers general surgery product in the areas of endoscopic technologies, including minimally invasive diagnostic and therapeutic products; critical care products cover a line of vital signs, cardiac monitoring, and patient care products, including ECG electrodes and accessories, cardiac defibrillation and pacing pads, and suction instruments and tubing; and physician\'s office electrosurgical product used by dermatologists. The company\'s products are used by surgeons and physicians in orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


1 Russell 2000 Stock on Our Buy List and 2 Facing Challenges

2026-03-20
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.

CAH Posts Strong Cash Flow, Eyes Next Steps in Capital Deployment

2026-03-19
CAH's $1.8 billion free cash flow fuels buybacks, dividends, and reinvestment, as Cardinal Health eyes disciplined capital deployment and targeted growth opportunities.

Micro-Tech Endoscopy Signs Definitive Agreement to Acquire Duraclip™, Precisor®, and Optibite® Product Lines from CONMED

2026-03-18
Micro-Tech Endoscopy today announced that it has entered into a definitive agreement to acquire the global distribution rights for the Duraclip™, Precisor®, and Optibite® product lines from CONMED Corporation and which CONMED has sold on behalf of Micro-Tech Endoscopy for over a decade.

[Latest] Global Surgical Stapling Devices Market Size/Share Worth USD 10.14 Billion by 2035 at a 7.2% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

2026-03-18
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Surgical Stapling Devices Market size & share revenue was valued at approximately USD 5.47 Billion in 2025 and is expected to reach USD 5.89 Billion in 2026 and is expected to reach around USD 10.14 Billion by 2035, at a CAGR of 7.2% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Medtronic plc, Ethicon

Piper Sandler Downgrades CONMED (CNMD)

2026-03-17

DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls

2026-03-17
DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls

Clearmind Medicine Submits Patent Application With Intellectual Property Department In Hong Kong

2026-03-13
Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, 

A Look At CONMED (CNMD) Valuation After Recent Weak Share Price Momentum

2026-03-12
CONMED (CNMD) has been on some investors’ radars after recent share performance, with the stock showing negative returns over the past month and past 3 months. This has prompted closer attention to its current valuation. See our latest analysis for CONMED. At a share price of $38.40, CONMED’s recent 7 day share price return of 10.68% decline and year to date share price return of 5.23% decline sit alongside a 1 year total shareholder return of 34.34% decline. Together, these moves point to...

3 Stocks Under $50 with Open Questions

2026-03-10
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.

Here's Why You Should Retain CONMED Stock in Your Portfolio Now

2026-03-10
CNMD's growth rests on AirSeal, Buffalo Filter and BioBrace as supply chains normalize, even as tariffs and a GI exit pressure EPS.